PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Safety and Tolerability of Six Months of Isoniazid or Three Months of Rifampicin for Tuberculosis Among Subjects With Diabetes Mellitus: A Randomized Trial
Tamez-Torres, K.M.; Mongua-Rodríguez, N.; Ferreyra-Reyes, L.; Torres-Gonzalez, P.; Delgado-Sánchez, G.; Martínez-Hernández, M.; Bobadilla-del-Valle, M.; Jasso-Sosa, V.Y.; López-Castillo, P.S.; Ferreira-Guerrero, E.; Cruz-Hervert, L.P.; Sifuentes-Osornio, J.; Aguilar-Salinas, C.A.; García-García, L.; Ponce-de-Leon, A. Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial. Microorganisms2023, 11, 1917.
Tamez-Torres, K.M.; Mongua-Rodríguez, N.; Ferreyra-Reyes, L.; Torres-Gonzalez, P.; Delgado-Sánchez, G.; Martínez-Hernández, M.; Bobadilla-del-Valle, M.; Jasso-Sosa, V.Y.; López-Castillo, P.S.; Ferreira-Guerrero, E.; Cruz-Hervert, L.P.; Sifuentes-Osornio, J.; Aguilar-Salinas, C.A.; García-García, L.; Ponce-de-Leon, A. Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial. Microorganisms 2023, 11, 1917.
Tamez-Torres, K.M.; Mongua-Rodríguez, N.; Ferreyra-Reyes, L.; Torres-Gonzalez, P.; Delgado-Sánchez, G.; Martínez-Hernández, M.; Bobadilla-del-Valle, M.; Jasso-Sosa, V.Y.; López-Castillo, P.S.; Ferreira-Guerrero, E.; Cruz-Hervert, L.P.; Sifuentes-Osornio, J.; Aguilar-Salinas, C.A.; García-García, L.; Ponce-de-Leon, A. Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial. Microorganisms2023, 11, 1917.
Tamez-Torres, K.M.; Mongua-Rodríguez, N.; Ferreyra-Reyes, L.; Torres-Gonzalez, P.; Delgado-Sánchez, G.; Martínez-Hernández, M.; Bobadilla-del-Valle, M.; Jasso-Sosa, V.Y.; López-Castillo, P.S.; Ferreira-Guerrero, E.; Cruz-Hervert, L.P.; Sifuentes-Osornio, J.; Aguilar-Salinas, C.A.; García-García, L.; Ponce-de-Leon, A. Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial. Microorganisms 2023, 11, 1917.
Abstract
Tuberculosis (TB) associated with diabetes (DM) is a growing problem, particularly in low and medium-resource countries. We conducted an open-label, parallel-group, randomized, and controlled trial in a tertiary care center in Mexico City to assess TB preventive treatment with isoniazid (INH) or rifampicin (RIF) in people with DM. Participants were assigned six months of INH 300mg/day plus pyridoxine 75mg or three months of RIF 600mg/day. The primary outcomes were adverse events resulting in permanent treatment cessation and considered possibly or probably related to study drugs. We included 130 subjects, 68 randomized to INH and 62 to RIF. We prematurely halted the study based on recommendations of the Adverse Event Safety Panel. There was no difference between arms in the overall frequency of adverse events. However, the INH group had significantly more permanent treatment interruptions due to grade 2 recurrent or grade 3 or 4 hepatoxicity. In comparison, the RIF arm had more treatment interruptions due to grade 3 or 4 gastrointestinal intolerance. TB preventive treatment is not safe enough to be considered a universal indication to patients with DM and LTBI. These results underline the need to search for alternative TB prevention in DM patients with better safety profiles.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.